FDA investigates risk of blood cancers from bluebird bio's gene therapy

bluebird bio

27/11/2024 16:38

Nov 27 (Reuters) - The U.S. Food and Drug Administration
said on Wednesday it is investigating reports of blood cancers
in patients who were treated with bluebird bio's  BLUE.O  gene
therapy Skysona.

 (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi
Majumdar)
 ((Christy.Santhosh@thomsonreuters.com))